SCHEMBL4292187

SCHEMBL4292187

N#C/C(=C\c1ccc(Br)cc1)c1ccncc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.64
KDM4E B2RXH2 7/20 0.64
ESR1 P03372 2/20 0.54
ESR2 Q92731 2/20 0.54
FTO Q9C0B1 1/20 0.48
RAB9A P51151 2/20 0.45
ALDH1A1 P00352 1/20 0.45
MAPK1 P28482 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
TUBB4A P04350 1/20 0.45
TUBB P07437 1/20 0.45
TUBA3C P0DPH7 1/20 0.45
TUBA1B P68363 1/20 0.45
TUBA4A P68366 1/20 0.45
TUBB4B P68371 1/20 0.45
TUBB3 Q13509 1/20 0.45
TUBB2A Q13885 1/20 0.45
TUBB8 Q3ZCM7 1/20 0.45
TUBA3E Q6PEY2 1/20 0.45
TUBA1A Q71U36 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4292191 1.00 MAPT (0.64) MAPTKDM4EESR1ESR2FTO
SCHEMBL4300288 0.93 KDM4E (0.68) MAPTKDM4EESR1ESR2FTO
SCHEMBL13659593 0.93 KDM4E (0.68) MAPTKDM4EESR1ESR2FTO
SCHEMBL4300285 0.93 KDM4E (0.68) MAPTKDM4EESR1ESR2FTO
SCHEMBL9610045 0.88 ESR1 (0.69) MAPTKDM4EESR1ESR2RAB9A
SCHEMBL13485338 0.88 ESR1 (0.69) MAPTKDM4EESR1ESR2RAB9A
SCHEMBL8511944 0.88 ESR1 (0.69) MAPTKDM4EESR1ESR2RAB9A
SCHEMBL30844141 0.84 ESR1 (0.63) MAPTKDM4EESR1ESR2FTO
SCHEMBL25220961 0.83 ESR1 (0.54) MAPTKDM4EESR1ESR2FTO
SCHEMBL6222549 0.83 ESR1 (0.54) MAPTKDM4EESR1ESR2FTO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090258852-A1 Inhibitors of Checkpoint Kinases MERCK SHARP & DOHME CORP. 2009-10-15 US disclosed
US-20090258852-A1 Inhibitors of Checkpoint Kinases MERCK SHARP & DOHME CORP. 2009-10-15 US disclosed
US-20090258852-A1 Inhibitors of Checkpoint Kinases MERCK SHARP & DOHME CORP. 2009-10-15 US disclosed
EP-1904449-A2 INHIBITORS OF CHECKPOINT KINASES Merck & Co., Inc. (US) 2008-04-02 EP disclosed
WO-2007008502-A2 INHIBITORS OF CHECKPOINT KINASES MERCK & CO., INC. (US) 2007-01-18 WO disclosed
WO-2007008502-A2 INHIBITORS OF CHECKPOINT KINASES MERCK & CO., INC. (US) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090258852-A1 Inhibitors of Checkpoint Kinases CHEK1, CHEK2, CDKN1A MAPT 3674/4885KDM4E 366/4885ESR1 2489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.